Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: A retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Naeim, Arash ^a   Henk, Henry J ^b   Becker, Laura ^b   Chia, Victoria ^c   Badre, Sejal ^c   Li, Xiaoyan ^c   Deeter, Robert ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OPTUM   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; ICD-9; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT DURATION; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; ODDS RATIO; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84871991303     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-11     Document Type: Article

References (29)

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005, 103(9):1916-1924. 10.1002/cncr.20983, 15751024.
2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100(2):228-237. 10.1002/cncr.11882, 14716755.
3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106(10):2258-2266. 10.1002/cncr.21847, 16575919.
4. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998, 34(12):1857-1864. 10.1016/S0959-8049(98)00222-6, 10023306.
5. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002, 62(Suppl 1):65-78.
6. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005, 10(6):427-437. 10.1634/theoncologist.10-6-427, 15967836.
7. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008, 19(3):454-460.
8. Weycker D, Malin J, Glass A, Oster G. Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol 2007, 5(2):44-45.
9. Schilling MBPC, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med 2011, 2:859-866. 3440789, 22977589.
10. Kozma CDM, Chia V, Legg L, Barron R. Trends in Neutropenia-Related Inpatient Events. J Oncol Pract Epub ahead of print, Jan. 31, 2012.
11. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24(19):3187-3205. 10.1200/JCO.2006.06.4451, 16682719.
12. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors http://www.nccn.org].
13. Morrison VA CV, Fridman M, Delgado DJ. A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients 2004, 742. Alexandria, Virginia: Proceedings of the American Society of Clinical Oncology Annual Meeting: 2004: 742. Abstract 8068, http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2445.
14. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14(1):29-35. 10.1093/annonc/mdg019, 12488289.
15. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003, 44(9):1503-1508. 10.1080/1042819031000103953, 14565651.
16. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002, 13(6):903-909. 10.1093/annonc/mdf130, 12123336.
17. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002, 20(3):727-731. 10.1200/JCO.20.3.727, 11821454.
18. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003, 21(3):514-519. 10.1200/JCO.2003.03.040, 12560443.
19. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother 2006, 40(3):402-407. 10.1345/aph.1G516, 16492793.
20. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007, 13(4):337-348.
21. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009, 31(5):1069-1081. 10.1016/j.clinthera.2009.05.019, 19539108.
22. Tan HTK, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 2011, 27:79-86. 10.1185/03007995.2010.536527, 21091127.
23. Weycker DMJ, Barron R, Edelsberg J, Kartashov A, Oster G. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol Epub ahead of print, March 2, 2011.
24. Department of Health and Human Services, Code of Federal Regulations Protection of human subjects Washington DC, Code Fed Regul Public Welfare 1995, http://www.hhs.gov/ohrp/policy/ohrpregulations.pdf. Title 45(Sections 46-101 to 46-409):Unknown, Department of Health and Human Services, Code of Federal Regulations.
25. Department of Health and Human Services, Code of Federal Regulations Health Insurance Portability and Accountability Act of 1996. Public Law 104-191. US Statut Large 1996, 110:1936-2103. http://aspe.hhs.gov/admnsimp/pl104191.htm, Department of Health and Human Services, Code of Federal Regulations.
26. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects [http://www.wma.net/en/30publications/10policies/b3/index.html].
27. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43(11):1130-1139. 10.1097/01.mlr.0000182534.19832.83, 16224307.
28. Fortner BV, Okon TA, Zhu L, Tauer K, Moore K, Templeton D, Schwartzberg L. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. Commun Oncol 2004, 1(1):23-28.
29. Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone 2006, 8(Suppl 5):S12-S18.